we also entered into a three-year senior secured asset-based revolving credit facility for up to $ 30.0 million . during the 2016 year , we launched 11 products . in 2017 , we acquired the right , title , and interest in the ndas and the u.s. rights to market atacand , atacand hct , arimidex , and casodex . in addition , we acquired the nda , trademarks , and certain finished goods inventory for inderal xl and innopran xl . we also entered into a $ 125.0 million five-year senior secured credit facility ( the “ credit agreement ” ) comprised of a $ 75.0 million five-year term loan ( the “ term loan ” ) and a $ 50.0 million senior secured revolving credit facility ( the “ revolving credit facility ” ) . during the 2017 year , we launched six products . 37 in 2018 , our subsidiary , ani pharmaceuticals canada inc. ( “ ani canada ” ) , acquired all the issued and outstanding equity interests of wellspring pharma services inc. ( “ wellspring ” ) , a canadian company that performs contract development and manufacturing of pharmaceutical products . in conjunction with the transaction , we acquired wellspring 's pharmaceutical manufacturing facility , laboratory , and offices , its current book of commercial business , as well as an organized workforce . following the consummation of the transaction , wellspring was merged into ani canada with the resulting entity 's name being ani pharmaceuticals canada inc. in addition , we acquired the andas for three previously-commercialized generic products , the approved andas for two generic products that have yet to be commercialized , the development package for one generic product , a license , supply , and distribution agreement for a generic product with an anda that is pending approval , and certain manufacturing equipment required to manufacture one of the products . we also acquired the andas for 23 previously-marketed generic products and api for four of the acquired products . during the 2018 year , we launched 11 products . in addition , in december 2018 , we refinanced our $ 125.0 million credit agreement by entering into an amended and restated senior secured credit facility ( the “ credit facility ” ) for up to $ 265.2 million . the principal new feature of the credit facility was a $ 118.0 million delayed draw term loan ( the “ ddtl ” ) , which could only be drawn on in order to pay down the company 's remaining 3.0 % convertible senior notes , which matured in december 2019. the credit facility also extended the maturity of the $ 72.2 million secured term loan to december 2023. in addition , the credit facility increased the previous $ 50.0 million line of credit ( the “ revolver ” ) to $ 75.0 million . in 2019 , we entered into an agreement with teva pharmaceutical industries ltd. to purchase a basket of andas for 35 previously-marketed generic drug products . we also acquired from coeptis pharmaceuticals , inc. seven development stage generic products . during the 2019 year , we launched six products . additionally , on november 29 , 2019 , we exercised our option to borrow $ 118.0 million pursuant to the ddtl feature under the existing credit facility and the proceeds were used to repay the outstanding 3 % convertible senior notes , which matured on december 1 , 2019. fiscal 2019 developments asset acquisitions in march 2019 , we entered into an agreement with teva pharmaceutical industries ltd. to purchase a basket of andas for 35 previously-marketed generic drug products for $ 2.5 million in cash . the transaction closed in march 2019 and we made the $ 2.5 million payment using cash on hand . in june 2019 , we acquired from coeptis pharmaceuticals , inc. seven development stage generic products , as well as active pharmaceutical ingredient ( “ api ” ) and reference-listed drug inventory related to certain of the products for a payment of $ 2.3 million . the entire payment , and $ 24 thousand of transaction costs directly related to the acquisition , was recorded as research and development expense because the potential generic products have significant remaining work required in order to commercialize the products and do not have an alternative future use . in addition , we could make up to $ 12.0 million in payments for certain development and commercial milestones . amendment to teva pharmaceuticals asset purchase agreement in january 2019 , we entered into an amendment to three asset purchase agreements ( the “ asset purchase agreement amendment ” ) with teva pharmaceuticals usa , inc. ( “ teva ” ) . under the terms of the asset purchase agreement amendment , all royalty obligations of the company owed to teva with respect to products associated with ten andas under the original asset purchase agreements ceased being effective as of december 31 , 2018. as consideration for the termination of such future royalty obligations , we paid teva a sum of $ 16.0 million . product launches in march 2019 , we launched two additional presentations of erythromycin ethylsuccinate for oral suspension . erythromycin ethylsuccinate is indicated in the treatment of infections caused by susceptible strains of selected diseases . in september 2019 , we launched vancomycin hydrochloride for oral solution , which is a prescription medication administered orally for treatment of enterocolitis caused by staphylococcus aureus , including methicillin-resistant strains , and antibiotic-associated pseudomembranous colitis caused by clostridium difficile . 38 in october 2019 , we launched aspirin and extended release dipyridamole capsules , which are indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis . in december 2019 , we launched bretylium tosylate injection usp 50mg/ml . story_separator_special_tag our effective tax rate for the year ended december 31 , 2018 was impacted primarily by the tax cuts and jobs act of 2017 , which was enacted on december 22 , 2017 and lowered the u.s. corporate tax rate from 35 % to 21 % , which began in 2018. our effective tax rate was also impacted by the discrete impact of current period awards of stock-based compensation , stock option exercises , and disqualifying dispositions of incentive stock options , all of which impact the consolidated effective rate in the period in which they occur . 44 story_separator_special_tag 31 , 2019 , we had not drawn on the revolver . 46 we may at any time repay borrowings under the term loans , including the initial term loan and ddtl , and the revolver without any premium or penalty , and we must repay all borrowings thereunder by december 27 , 2023. we may use the proceeds of the revolver for working capital and other general corporate purposes . amounts drawn under the term loan and ddtl bear an interest rate equal to , at our option , either a libor rate plus 1.50 % to 2.75 % per annum , depending on our total leverage ratio or an alternative base rate plus an applicable base rate margin , which varies within a range of 0.50 % to 1.75 % , depending our total leverage ratio . on the revolver , we incur a commitment fee at a rate per annum that varies within a range of 0.25 % to 0.50 % , depending on our leverage ratio . we must comply with various customary financial and non-financial covenants under the credit facility . the primary financial covenants under the credit facility consist of a maximum total leverage ratio , which initially shall be no greater than 3.75 to 1.00 and a minimum fixed charge coverage ratio which shall be greater than or equal to 1.25 to 1.00. the primary non-financial covenants under the credit agreement limit , subject to various exceptions , the company 's ability to incur future indebtedness , to place liens on assets , to pay dividends or make other distributions on the company 's capital stock , to repurchase the company 's capital stock , to conduct acquisitions , to alter its capital structure and to dispose of assets . in december 2017 , we entered into a $ 125.0 million credit agreement with citizens bank , n.a , which was replaced by the $ 265.2 million credit facility described above . the credit agreement was comprised of a $ 75.0 million five-year term loan and a $ 50.0 million senior secured revolving credit facility and was secured by the assets of the company . the funds from the term loan were used to pay down the $ 25.0 million balance on our existing line of credit , as well as to purchase the right , title , and interest in the ndas and the u.s. rights to market atacand , atacand hct , arimidex , and casodex , for $ 46.5 million in cash , as noted above . in december 2014 , we issued $ 143.8 million of 3.0 % convertible senior notes in a registered public offering ( the “ december 2014 offering ” ) , which includes the $ 18.8 million of notes issued pursuant to the full exercise of the over-allotment option granted to the underwriters in the december 2014 offering . after deducting the underwriting discounts and commissions and other expenses ( including the net cost of the bond hedge and warrant , discussed below ) , the net proceeds from the offering were approximately $ 122.6 million . in december 2018 , we repurchased $ 25.0 million of our outstanding notes . at the same time , we unwound a corresponding portion of the bond hedge and warrant , which are described in further detail below . as a result of unwinding this portion of the bond hedge and warrant , we received a net amount of $ 0.4 million . the remaining notes were convertible into 1,709,002 shares of common stock , based on an initial conversion price of $ 69.48 per share . a portion of the offering proceeds was used to simultaneously enter into “ bond hedge ” ( or purchased call ) and “ warrant ” ( or written call ) transactions with an affiliate of one of the offering underwriters ( collectively , the “ call option overlay ” ) . we entered into the call option overlay to synthetically raise the initial conversion price of the notes to $ 96.21 per share and reduce the potential common stock dilution that may arise from the conversion of the notes . the exercise price of the bond hedge was $ 69.48 per share , with an underlying 1,709,002 common shares ; the exercise price of the warrant is $ 96.21 per share , also with an underlying 1,709,002 common shares remaining as of december 31 , 2019. customer payments in addition to the financings in prior years , payments from customers are a significant source of cash in 2019 , 2018 , and 2017 and were our primary source of cash in 2019 and 2018. uses of cash our primary cash requirements are to fund operations , including research and development programs and collaborations , to support general and administrative activities , to purchase equipment and machinery to expand our manufacturing capabilities as our product lines grow , and to expand our business and product pipeline through acquisitions of products and companies . we are continually evaluating potential asset acquisitions and business combinations . our future capital requirements will depend on many factors , including , but not limited to : · product mix and pricing for product sales and contract manufacturing ; · pricing and payment terms with customers ; · costs of raw materials and payment terms with suppliers ;

liquidity and capital resources the following table highlights selected liquidity and working capital information from our consolidated balance sheets . replace_table_token_7_th at december 31 , 2019 , we had $ 62.3 million in unrestricted cash and cash equivalents . at december 31 , 2018 , we had $ 43.0 million in unrestricted cash and cash equivalents . we generated $ 45.6 million of cash from operations in the year ended december 31 , 2019. in june 2019 , we acquired from coeptis pharmaceuticals , inc. seven development stage generic products , as well as active pharmaceutical ingredient api and reference-listed drug inventory related to certain of the products for a payment of $ 2.3 million using cash on hand . in addition , we could make up to $ 12.0 million in payments for certain development and commercial milestones . in march 2019 , we purchased from teva pharmaceutical industries ltd. a basket of andas for 35 previously-marketed generic drug products for $ 2.5 million using cash on hand . in january 2019 , we entered into the asset purchase agreement amendment , under which all royalty obligations the company owed to teva with respect to products associated with ten andas under the original asset purchase agreements ceased being effective as of december 31 , 2018. as consideration for the termination of such future royalty obligations , we paid teva $ 16.0 million using cash on hand . in december 2018 , we refinanced our $ 125.0 million credit agreement by entering into an amended and restated senior secured credit facility ( the “ credit facility ” ) for up to $ 265.2 million .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```liquidity and capital resources the following table highlights selected liquidity and working capital information from our consolidated balance sheets . replace_table_token_7_th at december 31 , 2019 , we had $ 62.3 million in unrestricted cash and cash equivalents . at december 31 , 2018 , we had $ 43.0 million in unrestricted cash and cash equivalents . we generated $ 45.6 million of cash from operations in the year ended december 31 , 2019. in june 2019 , we acquired from coeptis pharmaceuticals , inc. seven development stage generic products , as well as active pharmaceutical ingredient api and reference-listed drug inventory related to certain of the products for a payment of $ 2.3 million using cash on hand . in addition , we could make up to $ 12.0 million in payments for certain development and commercial milestones . in march 2019 , we purchased from teva pharmaceutical industries ltd. a basket of andas for 35 previously-marketed generic drug products for $ 2.5 million using cash on hand . in january 2019 , we entered into the asset purchase agreement amendment , under which all royalty obligations the company owed to teva with respect to products associated with ten andas under the original asset purchase agreements ceased being effective as of december 31 , 2018. as consideration for the termination of such future royalty obligations , we paid teva $ 16.0 million using cash on hand . in december 2018 , we refinanced our $ 125.0 million credit agreement by entering into an amended and restated senior secured credit facility ( the “ credit facility ” ) for up to $ 265.2 million .
```    
 Suspicious Activity Report : we also entered into a three-year senior secured asset-based revolving credit facility for up to $ 30.0 million . during the 2016 year , we launched 11 products . in 2017 , we acquired the right , title , and interest in the ndas and the u.s. rights to market atacand , atacand hct , arimidex , and casodex . in addition , we acquired the nda , trademarks , and certain finished goods inventory for inderal xl and innopran xl . we also entered into a $ 125.0 million five-year senior secured credit facility ( the “ credit agreement ” ) comprised of a $ 75.0 million five-year term loan ( the “ term loan ” ) and a $ 50.0 million senior secured revolving credit facility ( the “ revolving credit facility ” ) . during the 2017 year , we launched six products . 37 in 2018 , our subsidiary , ani pharmaceuticals canada inc. ( “ ani canada ” ) , acquired all the issued and outstanding equity interests of wellspring pharma services inc. ( “ wellspring ” ) , a canadian company that performs contract development and manufacturing of pharmaceutical products . in conjunction with the transaction , we acquired wellspring 's pharmaceutical manufacturing facility , laboratory , and offices , its current book of commercial business , as well as an organized workforce . following the consummation of the transaction , wellspring was merged into ani canada with the resulting entity 's name being ani pharmaceuticals canada inc. in addition , we acquired the andas for three previously-commercialized generic products , the approved andas for two generic products that have yet to be commercialized , the development package for one generic product , a license , supply , and distribution agreement for a generic product with an anda that is pending approval , and certain manufacturing equipment required to manufacture one of the products . we also acquired the andas for 23 previously-marketed generic products and api for four of the acquired products . during the 2018 year , we launched 11 products . in addition , in december 2018 , we refinanced our $ 125.0 million credit agreement by entering into an amended and restated senior secured credit facility ( the “ credit facility ” ) for up to $ 265.2 million . the principal new feature of the credit facility was a $ 118.0 million delayed draw term loan ( the “ ddtl ” ) , which could only be drawn on in order to pay down the company 's remaining 3.0 % convertible senior notes , which matured in december 2019. the credit facility also extended the maturity of the $ 72.2 million secured term loan to december 2023. in addition , the credit facility increased the previous $ 50.0 million line of credit ( the “ revolver ” ) to $ 75.0 million . in 2019 , we entered into an agreement with teva pharmaceutical industries ltd. to purchase a basket of andas for 35 previously-marketed generic drug products . we also acquired from coeptis pharmaceuticals , inc. seven development stage generic products . during the 2019 year , we launched six products . additionally , on november 29 , 2019 , we exercised our option to borrow $ 118.0 million pursuant to the ddtl feature under the existing credit facility and the proceeds were used to repay the outstanding 3 % convertible senior notes , which matured on december 1 , 2019. fiscal 2019 developments asset acquisitions in march 2019 , we entered into an agreement with teva pharmaceutical industries ltd. to purchase a basket of andas for 35 previously-marketed generic drug products for $ 2.5 million in cash . the transaction closed in march 2019 and we made the $ 2.5 million payment using cash on hand . in june 2019 , we acquired from coeptis pharmaceuticals , inc. seven development stage generic products , as well as active pharmaceutical ingredient ( “ api ” ) and reference-listed drug inventory related to certain of the products for a payment of $ 2.3 million . the entire payment , and $ 24 thousand of transaction costs directly related to the acquisition , was recorded as research and development expense because the potential generic products have significant remaining work required in order to commercialize the products and do not have an alternative future use . in addition , we could make up to $ 12.0 million in payments for certain development and commercial milestones . amendment to teva pharmaceuticals asset purchase agreement in january 2019 , we entered into an amendment to three asset purchase agreements ( the “ asset purchase agreement amendment ” ) with teva pharmaceuticals usa , inc. ( “ teva ” ) . under the terms of the asset purchase agreement amendment , all royalty obligations of the company owed to teva with respect to products associated with ten andas under the original asset purchase agreements ceased being effective as of december 31 , 2018. as consideration for the termination of such future royalty obligations , we paid teva a sum of $ 16.0 million . product launches in march 2019 , we launched two additional presentations of erythromycin ethylsuccinate for oral suspension . erythromycin ethylsuccinate is indicated in the treatment of infections caused by susceptible strains of selected diseases . in september 2019 , we launched vancomycin hydrochloride for oral solution , which is a prescription medication administered orally for treatment of enterocolitis caused by staphylococcus aureus , including methicillin-resistant strains , and antibiotic-associated pseudomembranous colitis caused by clostridium difficile . 38 in october 2019 , we launched aspirin and extended release dipyridamole capsules , which are indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis . in december 2019 , we launched bretylium tosylate injection usp 50mg/ml . story_separator_special_tag our effective tax rate for the year ended december 31 , 2018 was impacted primarily by the tax cuts and jobs act of 2017 , which was enacted on december 22 , 2017 and lowered the u.s. corporate tax rate from 35 % to 21 % , which began in 2018. our effective tax rate was also impacted by the discrete impact of current period awards of stock-based compensation , stock option exercises , and disqualifying dispositions of incentive stock options , all of which impact the consolidated effective rate in the period in which they occur . 44 story_separator_special_tag 31 , 2019 , we had not drawn on the revolver . 46 we may at any time repay borrowings under the term loans , including the initial term loan and ddtl , and the revolver without any premium or penalty , and we must repay all borrowings thereunder by december 27 , 2023. we may use the proceeds of the revolver for working capital and other general corporate purposes . amounts drawn under the term loan and ddtl bear an interest rate equal to , at our option , either a libor rate plus 1.50 % to 2.75 % per annum , depending on our total leverage ratio or an alternative base rate plus an applicable base rate margin , which varies within a range of 0.50 % to 1.75 % , depending our total leverage ratio . on the revolver , we incur a commitment fee at a rate per annum that varies within a range of 0.25 % to 0.50 % , depending on our leverage ratio . we must comply with various customary financial and non-financial covenants under the credit facility . the primary financial covenants under the credit facility consist of a maximum total leverage ratio , which initially shall be no greater than 3.75 to 1.00 and a minimum fixed charge coverage ratio which shall be greater than or equal to 1.25 to 1.00. the primary non-financial covenants under the credit agreement limit , subject to various exceptions , the company 's ability to incur future indebtedness , to place liens on assets , to pay dividends or make other distributions on the company 's capital stock , to repurchase the company 's capital stock , to conduct acquisitions , to alter its capital structure and to dispose of assets . in december 2017 , we entered into a $ 125.0 million credit agreement with citizens bank , n.a , which was replaced by the $ 265.2 million credit facility described above . the credit agreement was comprised of a $ 75.0 million five-year term loan and a $ 50.0 million senior secured revolving credit facility and was secured by the assets of the company . the funds from the term loan were used to pay down the $ 25.0 million balance on our existing line of credit , as well as to purchase the right , title , and interest in the ndas and the u.s. rights to market atacand , atacand hct , arimidex , and casodex , for $ 46.5 million in cash , as noted above . in december 2014 , we issued $ 143.8 million of 3.0 % convertible senior notes in a registered public offering ( the “ december 2014 offering ” ) , which includes the $ 18.8 million of notes issued pursuant to the full exercise of the over-allotment option granted to the underwriters in the december 2014 offering . after deducting the underwriting discounts and commissions and other expenses ( including the net cost of the bond hedge and warrant , discussed below ) , the net proceeds from the offering were approximately $ 122.6 million . in december 2018 , we repurchased $ 25.0 million of our outstanding notes . at the same time , we unwound a corresponding portion of the bond hedge and warrant , which are described in further detail below . as a result of unwinding this portion of the bond hedge and warrant , we received a net amount of $ 0.4 million . the remaining notes were convertible into 1,709,002 shares of common stock , based on an initial conversion price of $ 69.48 per share . a portion of the offering proceeds was used to simultaneously enter into “ bond hedge ” ( or purchased call ) and “ warrant ” ( or written call ) transactions with an affiliate of one of the offering underwriters ( collectively , the “ call option overlay ” ) . we entered into the call option overlay to synthetically raise the initial conversion price of the notes to $ 96.21 per share and reduce the potential common stock dilution that may arise from the conversion of the notes . the exercise price of the bond hedge was $ 69.48 per share , with an underlying 1,709,002 common shares ; the exercise price of the warrant is $ 96.21 per share , also with an underlying 1,709,002 common shares remaining as of december 31 , 2019. customer payments in addition to the financings in prior years , payments from customers are a significant source of cash in 2019 , 2018 , and 2017 and were our primary source of cash in 2019 and 2018. uses of cash our primary cash requirements are to fund operations , including research and development programs and collaborations , to support general and administrative activities , to purchase equipment and machinery to expand our manufacturing capabilities as our product lines grow , and to expand our business and product pipeline through acquisitions of products and companies . we are continually evaluating potential asset acquisitions and business combinations . our future capital requirements will depend on many factors , including , but not limited to : · product mix and pricing for product sales and contract manufacturing ; · pricing and payment terms with customers ; · costs of raw materials and payment terms with suppliers ;

